CN101262874A - 稳定化的glp-1类似物 - Google Patents

稳定化的glp-1类似物 Download PDF

Info

Publication number
CN101262874A
CN101262874A CNA2006800331050A CN200680033105A CN101262874A CN 101262874 A CN101262874 A CN 101262874A CN A2006800331050 A CNA2006800331050 A CN A2006800331050A CN 200680033105 A CN200680033105 A CN 200680033105A CN 101262874 A CN101262874 A CN 101262874A
Authority
CN
China
Prior art keywords
glp
analog
amino acid
acid residue
aminoacid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800331050A
Other languages
English (en)
Chinese (zh)
Inventor
W·W·巴乔夫钦
D·G·桑福德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of CN101262874A publication Critical patent/CN101262874A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
CNA2006800331050A 2005-09-08 2006-09-07 稳定化的glp-1类似物 Pending CN101262874A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71532205P 2005-09-08 2005-09-08
US60/715,322 2005-09-08

Publications (1)

Publication Number Publication Date
CN101262874A true CN101262874A (zh) 2008-09-10

Family

ID=37836409

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800331050A Pending CN101262874A (zh) 2005-09-08 2006-09-07 稳定化的glp-1类似物

Country Status (11)

Country Link
US (1) US8318668B2 (https=)
EP (2) EP2497781A1 (https=)
JP (1) JP2009507844A (https=)
KR (1) KR20080052649A (https=)
CN (1) CN101262874A (https=)
AU (1) AU2006287562B2 (https=)
BR (1) BRPI0615573A2 (https=)
CA (1) CA2621699A1 (https=)
IL (1) IL189996A0 (https=)
NO (1) NO20081654L (https=)
WO (1) WO2007030519A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108271373A (zh) * 2015-06-10 2018-07-10 免疫医疗有限公司 蛋白酶抗性脂化glp-1类似物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE549028T1 (de) * 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1
WO2009149148A2 (en) * 2008-06-03 2009-12-10 Trustees Of Tufts College Long-acting glp-1 derivatives, and methods of treating cardiac dysfunction
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
JP5819946B2 (ja) * 2010-05-17 2015-11-24 ベータ ファーマシューティカルズ カンパニー リミテッド 新規のグルカゴン様ペプチド類似体、組成物、および使用方法
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
EP2630965A1 (en) * 2012-02-24 2013-08-28 Curatis Pharma GmbH A polypeptide for the protection from neurodegeneration in patients with amyotrophic lateral sclerosis (ALS)
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
JP5910901B1 (ja) * 2015-03-27 2016-04-27 株式会社東洋新薬 Ｇｌｐ−１分泌促進剤
MX2020010505A (es) 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
JP7221385B2 (ja) * 2018-10-30 2023-02-13 リウ、チアンニン Ｇｌｐ－１受容体アゴニスト活性を有するｇｌｐ－１ポリペプチドおよびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2131315A1 (en) 1992-03-25 1993-09-30 Geert J. Ensing Method of intraoperatively detecting and locating tumoral tissues
DK0678018T3 (da) 1993-01-06 2003-04-28 Kinerton Ltd Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
ATE408414T1 (de) * 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP1432430A4 (en) * 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
KR20040054729A (ko) * 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
ATE549028T1 (de) 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108271373A (zh) * 2015-06-10 2018-07-10 免疫医疗有限公司 蛋白酶抗性脂化glp-1类似物
CN108271373B (zh) * 2015-06-10 2021-12-28 免疫医疗有限公司 蛋白酶抗性脂化glp-1类似物

Also Published As

Publication number Publication date
EP2497781A1 (en) 2012-09-12
CA2621699A1 (en) 2007-03-15
WO2007030519A2 (en) 2007-03-15
AU2006287562A1 (en) 2007-03-15
EP1940438A4 (en) 2009-10-21
IL189996A0 (en) 2008-08-07
US8318668B2 (en) 2012-11-27
EP1940438A2 (en) 2008-07-09
US20090306338A1 (en) 2009-12-10
NO20081654L (no) 2008-04-03
BRPI0615573A2 (pt) 2011-05-24
AU2006287562B2 (en) 2012-05-10
WO2007030519A3 (en) 2007-11-29
KR20080052649A (ko) 2008-06-11
JP2009507844A (ja) 2009-02-26

Similar Documents

Publication Publication Date Title
JP4699374B2 (ja) 安定なペプチド及びポリペプチドアナログ治療剤
ES2319936T3 (es) Metodos para regular la motilidad gastrointestinal.
JP4282485B2 (ja) 伸長グルカゴン様ペプチド−１アナログ
CA2837710C (en) Pegylated oxyntomodulin conjugates with improved linkers
EP2565205B1 (en) Glucagon-like peptide-1 analogue and use thereof
US20240018208A1 (en) Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
JP2016147895A (ja) 自己免疫疾患の治療方法及びそれに関する試薬
KR20170073638A (ko) 글루카곤 및 glp-1 수용체의 공-효능제
KR20050083713A (ko) 안정화된 엑센딘-4 화합물
US11267861B2 (en) Peptide-oligourea foldamer compounds and methods of their use
CN101262874A (zh) 稳定化的glp-1类似物
US20260055155A1 (en) Incretin analog and use thereof
JP2008546816A (ja) エキセンディン４ポリペプチドフラグメントおよびその使用
CN119894921A (zh) Gip和glp-1双重激动剂化合物
KR101496136B1 (ko) 글루카곤 유사 펩타이드-1 유사체 및 이의 용도
CN120137001B (zh) 多肽化合物及其应用
CN119192298A (zh) 一类双位点偶联脂肪酸的BimBH3类似物及其制备方法与应用
RU2589258C1 (ru) Средство пептидной структуры, ингибирующее дипептидилпептидазу-4, и фармацевтическая композиция на его основе
CN121673371A (zh) 一类基于钉合与脂肪酸酰化双修饰策略构建的新型BimBH3模拟肽类似物及其制备方法和应用
WO2024213022A1 (zh) 肠促胰素类似物及其制备方法和应用
JP2012513981A (ja) Ｇｌｐ−１アナログおよびその使用
HK1088840B (en) Stable analogs of glp-1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20080910

C20 Patent right or utility model deemed to be abandoned or is abandoned